Product NewsHorizon Discovery Introduces Single Cell RNAseq-Linked CRISPR Screening Serviceby Horizon Discovery GroupSingle cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight
Product NewsCas9 and dCas9-VPR Stable Cell Lines to Simplify and Accelerate CRISPR Gene Editing Workflowsby Horizon Discovery Group
Product NewsHorizon Discovery Extends Coverage of OncoSpan Reference Standards to FFPE and Liquid Biopsyby Horizon Discovery GroupOncoSpan range expanded to include FFPE and cfDNA formats to mimic solid tumors and liquid biopsy samples, respectively
Product NewsHorizon Discovery Expands Cell-Based CRISPR Screening Servicesby Horizon Discovery GroupNew arrayed B cell CRISPR knockout screening service strengthens support for development of therapeutics for diseases involving the immune system
Product NewsHorizon Discovery Signs Collaboration and License Agreement with Mammoth Biosciencesby Horizon Discovery GroupCompany aims to develop the next generation of engineered CHO cell lines to improve production of biotherapeutics
Product NewsHorizon Discovery to Provide Access to Novel Base Editing Technologyby Horizon Discovery GroupNext-generation gene editing system has applications in development of cell and gene therapies
NewsHorizon Discovery Partners with the Human Protein Atlasby Horizon Discovery GroupAgreement will expand open access resource, supporting genetic research globally
NewsHorizon Discovery Divests Animal Models Business to Envigoby Horizon Discovery GroupEnvigo, a leading global research model supplier, enters the gene-edited research model field with the addition of Horizon’s business
Product NewsHorizon Discovery Introduces Myeloid DNA Reference Standard to Support Genetic Testing of Leukemiaby Horizon Discovery GroupFirst-to-market cell line-derived reference standard for myeloid blood cancers
NewsHorizon Discovery Announces Collaboration with Major Pharmaceutical Company on Single Cell RNAseq-Linked CRISPR Screeningby Horizon Discovery GroupCo-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation